Gabapentin and pregabalin are used to treat neuropathic pain and some forms of epilepsy.
We already had gabapentin listed for people with epilepsy, neuropathic pain or pruritus related to chronic renal failure.
A commercial process resulted in funding both gabapentin and pregabalin without restrictions, with savings of $9.6 million.
Gabapentin accounted for approximately 53,000 Special Authority applications annually, the highest of any pharmaceutical. Removing the Special Authority has therefore significantly reduced the administrative burden for health professionals.
Last updated: 13 December 2018